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Abstract
Aims The relation of disease progression and age, serum interleukin 10 (IL-10) and interferon gamma (IFNc) and their
genetic correlates were studied in paediatric patients with newly diagnosed Type 1 diabetes.
Methods Two hundred and twenty-seven patients from the Hvidoere Study Group were classified in four different pro-
gression groups as assessed by change in stimulated C-peptide from 1 to 6 months. CA repeat variants of the IL-10 and IFNc
gene were genotyped and serum levels of IL-10 and IFNc were measured at 1, 6 and 12 months.
Results IL-10 decreased (P < 0.001) by 7.7% (1 month), 10.4% (6 months) and 8.6% (12 months) per year increase in
age of child, while a twofold higher C-peptide concentration at 1 month (p = 0.06), 6 months (P = 0.0003) and 12 months
(P = 0.02) was associated with 9.7%, 18.6% and 9.7% lower IL-10 levels, independent of each other. IL-10 concentrations
did not associate with the disease progression groups. By contrast, IFNc concentrations differed between the four pro-
gression groups at 6 and 12 months (P = 0.02 and P = 0.01, respectively); patients with rapid progressing disease had the
highest levels at both time points. Distribution of IL-10 and IFNc genotypes was equal among patients from the progression
groups.
Conclusion IL-10 serum levels associate inversely with age and C-peptide. As age and C-peptide also associate, a triangular
association is proposed. Genetic influence on IL-10 production seems to be masked by distinct disease mechanisms.
Increased serum IFNc concentrations associate with rapid disease progression. Functional genetic variants do not asso-
ciate with a single progression pattern group, implying that disease processes override genetically predisposed cytokine
production.
Diabet. Med. 29, 734–741 (2012)
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Introduction
Type 1 diabetes is an autoimmune disease [1,2]. After initiation
of insulin therapy, approximately 43–56% of the patients
develop a temporal remission of the disease, where the need for
exogenous insulin declines [3]. Based on changes in stimulated
C-peptide 1–6 months after diagnosis with Type 1 diabetes, we
have previously shown that newly diagnosed paediatric patients
have different patterns of loss in residual b-cell function,
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varying from rapid, to slow, to stable, or even to an increases
[4]. Several factors may contribute to remission, including
partial b-cell recovery [3], resolution of the inflammatory
process [5], improved insulin sensitivity and higher glucose
uptake in peripheral tissue [6]. Systemic cytokines associated
with autoimmunity may be involved in the destruction of the
b-cells [1].
Interferon gamma (IFNc) is a Th1 cytokine and may play a
role in the inflammation of the islets [7], while interleukin 10
(IL-10), a cytokine produced by regulatory T-cells, may protect
against development of Type 1 diabetes [8]. Several polymor-
phisms in the genes encoding for IFNc and IL-10 influence the
level of cytokine production. A CA microsatellite in the IFNc
gene has been linked to various autoimmune diseases, such as
multiple sclerosis, Grave’s disease, coeliac disease and Type 1
diabetes [9–12]. A CA repeat microsatellite in the IL-10 gene
has been shown to influence serum levels of IL-10 [13]. Previ-
ously, we found that the IFNc genotype, in combination with
serum IFNc concentration in patients with new-onset Type 1
diabetes (mainly adolescents and adults) was associated with
clinical remission defined as HbA1c < 58 mmol ⁄mol (7.5%)
and insulin dose < 0.38 U kg–1 24 h–1, while there were no
associations with either IL-10 levels or genotype frequencies
[14]. In this study, we tested the hypothesis that IL-10 and
IFNc serum levels in combination with their respective geno-
types are associated with disease progression in paediatric
patients with newly diagnosed Type 1 diabetes.We investigated
the relationship between cytokine serum levels, immunogenetic
predisposition and b-cell function and age and different patterns
of disease progression in the first year after diagnosis in
paediatric patients with newly diagnosed Type 1 diabetes.
Patients and methods
The Hvidoere Study
The study was nested within the framework of the Hvidoere
Study Group on Childhood Diabetes, which is a multi-centre
longitudinal investigation with 275 children under the age of
16 years with newly diagnosed Type 1 diabetes (144 girls and
131 boys, 84%white Caucasians). The median age at diagnosis
was 9.1 years (range 0.2–16.8) [15].
C-peptide measurements
Stimulated C-peptide was measured 1, 6 and 12 months post
diagnosis. In the morning, after at least 8 h of fasting, 6 ml ⁄kg
(maximum 360 ml) of Boost ⁄Sustacal [Mead Johnson, Evans-
ville, IN, USA; 237 ml (8 fluid ounces) contains 33 g carbo-
hydrate, 15 g protein and 6 g fat; 240 kcal total] was ingested
in less than 10 min. In agreement with the Diabetes Control
and Complications Trial protocol, capillary glucose was
measured at time 0 and venous C-peptide and glucose at
90 min after the ingestion of Boost. Serum samples were frozen
at –20 ºC until sent to the Steno Diabetes Centre, Denmark, on
dry ice for determination of C-peptide. Samples were thawed
only once for radioimmunoassay determination. C-peptide was
analysed in serum by an enzyme-linked immunosorbent assay
(Daco, Ely, UK) [15].
IL-10 and IFNc cytokine measurements
Serum levels of IL-10 and IFNc were determined by multiplex-
bead technology using commercially available kits (Fluorokine
MAP; R&D Systems, Minneapolis, MN, USA). The samples
were treated in a blinded fashion: no data of the patients were
available when the serum was tested. Detection limits for the
assays were 0.1 pg ⁄ml for both IL-10 and IFNc. Determination
of cytokine concentrations lower than detection limit were
assigned a value half of the detection limit (IL-10 1 month,
n = 19; IL-10 6 months, n = 20; IL-10 12 months, n = 16;
IFNc 1 month; n = 63, IFNc 6 months, n = 59; IFNc
12 months, n = 60). The immune assays showed interassay
variations < 20% and intra-assay variations < 10%.
IL-10 and IFNc genotyping
The IL-10G CA microsatellite is located in the promoter region
of the IL-10 gene [13]. Different variants of the CA repeat were
identified according to the length of CA repeats. All patients
were genotyped for a CA repeat in the first intron of the IFNc
gene. Genotyping of IFNc was successful for 197 (71.6%) of
the patients. Different variants of the CA repeat were identified
according to the length of these CA repeats. Genotyping was
carried out as previously described [16]. The allele and geno-
type frequencies of the IL-10 and IFNc genes were in Hardy–
Weinberg proportions. There were no associations between
age, gender and the variants of the IL-10 and IFNc genes.
Definition of Type 1 diabetes progression patterns
Within the Hvidoere study population, we have shown that
patients may be categorized into four progression patterns
groups based on longitudinal variations in the levels of stimu-
lated C-peptide from 1 to 6 months after diagnosis with Type 1
diabetes: (1) patients with ‘stable–low’ pattern, who had con-
stant low levels (< 100 pmol ⁄ l) of stimulated C-peptide; (2)
patients with a ‘rapid progresser’ pattern, who showed a
decline of more than 20% in C-peptide 1–6 months after
diagnosis; (3) patients with a ‘slow progresser’ pattern, who
had a slow decline in the levels of C-peptide of less than 20%;
and (4) patients with a ‘remitter’ pattern, who had an increase
in the levels of C-peptide of more than 20% [4]. From the study
base of 275 children (as mentioned above), 227 children (with
stimulated C-peptide measurements from both 1 and
6 months) were grouped in one of the four progression pattern
groups; 116 were girls and 111 boys, 85% were white
Caucasians and median age at diagnosis was 9.6 years (range
0.2–16.3). The progression pattern groups have been described
in detail in a previous paper. It was reported that the number of
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autoantibodies (GAD, IA-2 and IC antibodies) present in
patients from the four progression groups differed significantly
1 month (P = 0.04) after diagnosis, while no differences were
found at 6 or 12 months. All three autoantibodies were pres-
ent in all four groups and no difference in titres of specific
autoantibodies was found between the groups. Serum
concentrations of adiponectin, IL-1ra, interferon-inducible
protein 10 (IP-10) and IL-6 among the patients from the
four progression groups have been analysed [4]. Clinical
information, including BMI, HbA1c, diabetic ketoacidosis at
diagnosis and insulin dose, is summarized in Table 1.
Definition of genotypes profiles
The IL-10G CA repeat has previously been associated with a
high production of IL-10. The variant IL-10G14 has been
shown to be more frequent in patients with Type 1 diabetes
compared with healthy control subjects [13]. The number of
CA repeats in the IL-10G microsatellite varied from 10 to
14 bp in length, corresponding to variants 123–131 (123 =
10 CA, 125 = 11 CA, 127 = 12 CA; 129 allele = 13 CA and
131 allele = 14 CA). The variants 125 and 127 were the most
common in our study population (160 patients were carriers of
variant 125 and 88 were carriers of variant 127). Patients were
therefore categorized as carriers of two copies of the 125 allele
(125 ⁄125), as carriers of two copies of 127 (127 ⁄127), as
heterozygous for both variants (127 ⁄125) or as carriers of rare
variants (X ⁄X) (n = 10). The CA repeat in the first intron of the
IFNc gene has been associated with higher IFNc serum levels in
healthy control subjects. Further, the repeat has been associated
with Type 1 diabetes in a British population but not in Danish
and Finish patients [17,18]. For IFNc genotypes, patients were
categorized as non-carrier of the most common allele 190
(X ⁄X) (n = 58), as carriers of one copy of the 190 allele
(190 ⁄X) (n = 107) or as carriers of two copies of the 190 allele
(190 ⁄190) (n = 32).
Statistical methods
We addressed the study hypotheses in four steps and tested for
associations between: (1) serum levels of IL-10 and IFNc, and
levels of stimulated C-peptide as continuous variable; (2) age
and cytokine levels; (3) Type 1 diabetes progression, as assessed
by the progression groups and cytokine serum levels; and (4)
we examined the distribution of IL-10 and IFNc genotypes and
stimulated C-peptide of the four progression pattern groups.
The possible relationship between genotypes and progression
pattern groups was investigated using Fisher’s exact tests.
Ordinal regression analyses were used to investigate the pos-
sible relationships between IL-10 and IFNc serum levels and
C-peptide and age. Associations between cytokine and age were
adjusted for C-peptide. Multiple regression analyses were used
to investigate the relations of progression groups, stimulated
C-peptide, age, gender, IL-10 and IFNc serum levels and
genotypes at 1, 6 and 12 months. Twomodels were tested: (1) a
model with cytokine as the dependent variable and age, gender
and C-peptide as explanatory variables; (2) a model including
the cytokines levels as the dependent variable, and progression
pattern groups, age and gender as explanatory variables.
Cytokine and C-peptide values were log transformed to obtain
normal distributions. Associations are descriptive and were not
corrected for multiple testing. The statistical analysis was per-
formed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Hvidoere Study Group
Of the 227 patients with stimulated C-peptide data from 1 and
6 months, 10.2% (n = 23) had a stimulated C-peptide below
100 pmol ⁄ l, which remained low during the first 6 months,
and they were assigned to the stable–low group; 51.5%
(n = 117) had a rapid decline in stimulated C-peptide and they
Table 1 Clinical characteristics of patients from the four progression patterns groups
Progression
pattern group n
Gender
(male ⁄ female)
Age at
diagnosis
BMI (kg ⁄m2)
at 1 month
Ketoacidosis
(%) at
diagnosis
HbA1c%
1 month
HbA1c
mmol ⁄mol
1 month
Insulin dose kg–1
24 h–1 1 month
All patients 227 111 ⁄ 116 9.6
(0.2–16.3)
17.1
(12.3–33.1)
20.3 8.9
(6.2–12.4)
74
(44–112)
0.45
(0.1–2.7)
Stable–low 23 13 ⁄ 10 8.8
(0.7–14.7)
16.3
(12.6–23.0)
38.1 8.9
(6.2–12.4)
76
(44–112)
0.54
(0.1–1.1)
Rapid progressers 117 58 ⁄ 59 9.1
(1.1–16.3)
16.8
(12.3–33.1)
21.4 8.1
(6.3–11.8)
65
(45–105)
0.44
(0.1–3.0)
Slow progressers 54 24 ⁄ 30 10.9
(3.1–14.6)
17.4
(13.0–27.6)
12.5 9.1
(6.9–11.8)
76
(52–105)
0.45
(0.1–1.1)
Remitters 33 16 ⁄ 17 9.4
(0.2–15.4)
18.1
(12.6–23.0)
24.1 8.5
(6.5–11.9)
69
(48–107)
0.57
(0.1–1.3)
Age, BMI, HbA1c and insulin dose are shown as median (with range). Ketoacidosis is defined as HCO
3 < 15 and ⁄ or pH < 7.3. Age and
ketoacidosis are determined at diagnosis while HbA1c, BMI and insulin dose are estimated 1 month after diagnosis. Patients from the four
progression groups differed significantly in age (P = 0.04).
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were labelled as rapid progressers; 23.8% (n = 54) had a slow
decline and were grouped as slow progressers; while 14.5%
(n = 33) of the patients had an increase in stimulated C-peptide
and were assigned to the remitter group. As reported before,
the groups differed significantly in age (P = 0.04), stable–low
patients were younger compared with patients from the
other groups [4]. There were no differences among the groups
regarding ethnicity, gender, BMI, HbA1c, insulin dose kg
–1
24 h–1 and ketoacidosis at diagnosis (Table 1).
IL-10
In all patients, the mean  sem level of IL-10 was higher at
1 month (0.96  0.10) compared with month 6
(0.93  0.11 pg ⁄ml) and month 12 (0.88  0.16 pg ⁄ml).
Among all the patients, there was an inverse association
between serum levels of IL-10 and C-peptide, which was bor-
derline significant at 1 month (P = 0.06, estimate = –0.14), but
significant at 6 and 12 months (P = 0.0003, estimate = –0.27
and P = 0.02, estimate = –0.14), suggesting 9.7, 18.6 and
9.7% lower IL-10 level by a twofold higher C-peptide con-
centration at 1, 6 and 12 months, respectively (Fig. 1). The
association between C-peptide and IL-10 disappeared when
adjusted for age at 1, 6 and 12 months (P = 0.63, P = 0.06 and
P = 0.73, respectively). There was an inverse significant asso-
ciation between IL-10 levels and age at 1, 6 and 12 months
(P < 0.001, estimate = –0.08; P < 0.001 estimate = –0.11; and
P < 0.001 estimate = –0.09 at 1, 6 and 12 months, respec-
tively) suggesting 7.7, 10.4 and 8.6% decrease of IL-10 level
per year increase in age, which was unaffected by adjustment
for C-peptide. There was a positive significant association
between C-peptide and age at 1, 6 and 12 months (P < 0.0001,
estimate = 0.09; P < 0.0001, estimate = 0.09 and P < 0.0001,
estimate = 0.13 at 1, 6 and 12 months, respectively) suggesting
9.6, 9.6 and 13.6% higher C-peptide concentration per year
increase in age. We found no differences of serum IL-10 across
the groups, although there was a trend that patients with slow
progressing diseases had lower levels of IL-10 at all time points
(P = 0.08, Fig. 2).
Genotype frequencies of IL-10 gene variants were equal
among patients from the four progression pattern groups
(Fig. 3). In contrast to healthy subjects, functional genetic
variants of IL-10G were not associated with IL-10 serum levels
at any time point after disease onset.
IFNc
Among all patients, the mean values of IFNc serum concen-
trations (mean  sem) at 6 months (0.78  0.09 pg ⁄ml) and
12 months (0.77  0.12 pg ⁄ml) were higher than at 1 month
(0.66  0.06 pg ⁄ml). In addition, there was no association
between IFNc serum concentrations and age or stimulated
C-peptide at any time point. However, serum levels of IFNc
differed among patients from the four progression pattern
groups at 6 months (P = 0.02). Rapid progressing patients
showed the highest serum levels (mean  sem: 0.96  0.16
pg ⁄ml), followed by patients from the remitter group (0.68 
0.13 pg ⁄ml) and the slow progresser group (0.62 
0.16 pg ⁄ml), while stable–low patients had the lowest con-
centration (mean  sem: 0.44  0.13 pg ⁄ml). At 12 months,
the differences between the four progression groups remained
significant (P = 0.01), with rapid progressing and remitting
patients having the highest levels, compared with patients from
the slow progresser and stable–low groups (Fig. 2). Genotype
frequencies of the IFNc gene were equal among patients from
the four progression pattern groups (Fig. 3). IFNc genotypes
and serum levels of IFNc were moderately associated: patients
homozygous for the 190 variant had higher levels at 1 and
6 months (P = 0.07 and P = 0.02, respectively), compared with
heterozygous and non-carriers of 190.
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FIGURE 1 There was a significant inverse association between serum levels of IL-10 and stimulated C-peptide at 1 month (blue), 6 months (black) and
12 months (red), P = 0.06 (estimate –0.14), P = 0.0003 (estimate –0.27) and P = 0.02 (estimate –0.14), respectively, suggesting 9.7, 18.6 and 9.7% lower
IL-10 level at a twofold higher C-peptide concentration.
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There were no associations between stimulated C-peptide
and variants of the IL-10 and IFNc genes or between the serum
levels of the two cytokines.
Discussion
The results presented in this study could point to a trinity
between C-peptide, IL-10 serum concentration and age. While
IL-10 is thought to have a protective effect on development of
Type 1 diabetes through its down-regulating effect on Th1
cytokines and inhibitory effect on MHC class I expression
[8,13,19], our findings suggest negative associations between
IL-10 and C-peptide and age. We also report an association
between IFNc and different progression patterns.
The negative association between IL-10 and C-peptide is
counter-intuitive. Indeed, the frequency of natural regulatory
T-cells has been shown to increase with age [20]. IL-10 inhibits
inflammation and could therefore reflect attempts for regula-
tion of the autoimmune process. Deficiency in peripheral tol-
erance has been proposed to be important in the autoimmune
process leading to Type 1 diabetes [21]. In the healthy immune
system, auto-reactive T-cells are suppressed by regulatory
T-cells [8]. Studies have shown that the number of regulatory
T-cells is similar in patients with newly diagnosed or long-
standing Type 1 diabetes and healthy age-matched control
subjects [22,23]. Yet, the regulatory capacity of regulatory
T-cells is markedly reduced in patients with Type 1 diabetes,
while more recent studies suggest that effector T cells are
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FIGURE 2 Serum concentrations of IL-10 (red) and IFNc (blue) for the four progression pattern groups at 1, 6 and 12 months. The values are presented as
mean serum concentrations with sem. Serum IFNc differed significantly between the groups at 6 months (P = 0.02) and at 12 months (P = 0.01), rapid
progressing patients having the highest level, followed by patients from the remitter and slow progresser group, while stable–low patients had the lowest
level. There was also a significant difference at 12 months (P = 0.01), where rapid progressing and remitting patients had the highest levels followed by
patients from slow progressing and stable–low groups.
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FIGURE 3 (a) The most comment variants of the IL-10 gene among patients from the four progression pattern groups were 125, present in 168 of the
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group had 127 ⁄ 127, there were no significant differences in the distribution. (b) The most common variant of the IFNc gene among patients from the four
groups was 190, which was present in 139 of the patients. The genotypes were equally distributed among the four progression pattern groups.
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relatively resistant for regulation by regulatory T-cells [22,23].
As regulatory T-cells may inhibit effector T-cells via IL-10
production [24], it could be speculated that high levels of IL-10
seen in patients with low C-peptide production reflects resis-
tance of auto-reactive T-cells to immune regulation requiring
more IL-10. The rate of islet infiltration has been shown to be
similar in regulatory T-cell-deficient and normal non-obese
diabetic (NOD) mice [25]. This accords with the lack of
association between the progression pattern groups and IL-10.
Our findings are in line with previous reports that show low
levels of IL-10 at diagnosis correlate with later clinical remis-
sion [26]. Malfunction of regulatory T-cells as an explanation
for the negative association between IL-10 and C-peptide
warrants further investigation.
A positive association between stimulated C-peptide and age
is well established [27], but to our knowledge this study is the
first to report an inverse association between age and IL-10
serum concentrations in a paediatric population with newly
diagnosed Type 1 diabetes. We propose a triangular interaction
between age, IL-10 and C-peptide in children with newly
diagnosed Type 1 diabetes.
Positive correlations between age and IFNc, IL-2 and tumour
necrosis factor alpha (TNFa) have been described in healthy
individuals [27]. We found no association between IFNc and
age in paediatric patients shortly after clinical manifestation of
Type 1 diabetes. The negative association between IL-10 and
C-peptide could be mediated to some extent via the effect of
age on IL-10 and possibly more resistant auto-reactive T-cells
at young age, as suggested by our data.
The functional variant was not associated with serum IL-10
among patients, as opposed to what has been found in healthy
individuals [14]. Our study is not conclusive to exclude an
association, but we speculated that genetic influence on IL-10
production is masked by distinct disease mechanisms during
islet inflammation. It could be of interest to investigate IL-10
variants in another paediatric population with Type 1 diabetes,
in particular longer after disease manifestation.
IFNc is produced by natural killer cells and Th1 cells in
response to antigen recognition. IFNc is involved in the
development of Type 1 diabetes. However, conflicting reports
on whether IFNc genotypes influence the development of
Type 1 diabetes exist. In this study, we found no association
between IFNc serum levels and stimulated C-peptide and age.
While genotypes of IFNc influenced the serum concentration of
IFNc among the patients, which is in line with previous find-
ings in healthy control subjects [14], IFNc genotypes were not
associated with distinct patterns of disease progression. Yet,
even although the distribution of the genetic variants was equal
among the progression groups, rapidly progressing patients had
significantly higher levels of IFNc compared with other pro-
gression groups. Conversely, we have previously shown that
patients in clinical remission, defined by HbA1c £ 58 mmol ⁄ -
mol (7.5%) and insulin requirement £ 0.38 U kg–1 day–1, had
significantly lower IFNc levels than patients not in remission, in
spite of the presence of IFNc genotypes associated with high
IFNc production [14]. IFNc has been described as a key mol-
ecule in b-cell destruction [7]. However, a possible dichoto-
mous action of IFNc has been suggested [28]. Thus, IFNc
deficiency in NOD mice did not prevent Type 1 diabetes, but
only delayed disease onset [29]. Also, long-lasting protection
against Type 1 diabetes after exogenous treatment with IFNc
was shown in BioBreeding (BB) rats [30]. From a functional
perspective, our data support the proposed association of IFNc
with b-cell destruction in humans. Rapidly progressing patients
are believed to have a more active inflammatory process and
could therefore be expected to display higher levels of IFNc
compared with patients with other disease progression profiles.
At 12 months, remitting patients also had higher levels of
IFNc, possibly indicating an end to the partial remission phase.
Together with our aforementioned findings on IL-10, our
results support earlier reports that disease mechanisms overrule
functionality of IFNc gene polymorphisms, as only rapidly
progressing patients showed high serum IFNc concentrations in
two independent studies.
In conclusion, we propose that changes in stimulated
C-peptide can be used to stage different kinetics of Type 1 dia-
betes progression, which may prove valuable for understanding
factors affecting residual b-cell function and preservation after
diagnosis. High levels of IL-10 correlated with low levels of
residual b-cell function, which may reflect malfunction of regu-
latory T-cells. Further, we contend that age is important when
studying IL-10 and disease progression. The difference in IFNc
serum concentrations among patients with different progression
pattern suggests distinct mechanisms of disease progression.
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